Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Rhea-AI Summary

Abivax (Euronext/Nasdaq: ABVX) will hold its Annual Ordinary and Extraordinary General Meeting on May 11, 2026 at 3:00 pm CEST in Paris (Paris Marriott Opera Ambassador).

Preparatory documents, agenda and draft resolutions are available to shareholders on the company website and were published in BALO on April 3, 2026 (N°2600756).

News Market Reaction – ABVX

-3.09%

-3.09% Session close to close

In the Apr 21 session, ABVX declined 3.09%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the framework for Abivax’s ordinary and extraordinary general meeting on May ...

Analysis

This announcement sets the framework for Abivax’s ordinary and extraordinary general meeting on May 11, 2026, detailing the venue, time, agenda publication in BALO, and access to preparatory documents under Article R.22-10-23 of the French Commercial Code. It is primarily procedural, but investors should review the draft resolutions once available, focusing on any proposed changes to capital structure, governance, or strategic authorizations that could influence future corporate flexibility.

Key Figures

General Meeting date: May 11, 2026 Meeting time: 3:00 pm (CEST) Publication time: 10:05 PM CEST +4 more

7 metrics

General Meeting date May 11, 2026 Scheduled date of ordinary and extraordinary general meeting

Meeting time 3:00 pm (CEST) Scheduled time of the General Meeting

Publication time 10:05 PM CEST Time of press release on April 20, 2026

BALO notice date April 3, 2026 Date of preliminary meeting notice in BALO

BALO notice number N°2600756 Reference number of the BALO publication

Street address 16 boulevard Haussmann Location of Paris Marriott Opera Ambassador hotel for meeting

Postal code 75009 Postal code of meeting venue in Paris

Historical Context

5 past events · Latest: Apr 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 01	Regulatory filings posted	Neutral	+3.0%	Publication of Universal Registration Document and Form 20-F annual report.
Mar 23	Full-year 2025 results	Negative	-4.5%	Reported large 2025 net loss alongside business updates and cash runway detail.
Feb 21	Clinical data at ECCO	Positive	+2.0%	Presented 22 abstracts with anti-fibrotic evidence and supportive IBD efficacy data.
Jan 07	2026 corporate outlook	Positive	-8.7%	Outlined obefazimod plans, growing UC market projections and cash runway into Q4 2027.
Dec 18	Index inclusion	Positive	+1.2%	Announcement of inclusion in Nasdaq Biotechnology Index following Phase 3 progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows mostly aligned price reactions to news, with one notable divergence on a generally positive 2026 corporate outlook update.

Recent Company History

Over the past six months, Abivax has reported several milestones: inclusion in the Nasdaq Biotechnology Index on Dec 22, 2025, a positive 2026 corporate outlook with projected cash runway into Q4 2027, extensive efficacy and safety data at ECCO 2026, and full-year 2025 financial results with a €336.1M net loss but strengthened liquidity. Regulatory and reporting updates, including the Mar 23, 2026 Form 20-F filing, have generally seen modest positive or mixed market reactions. Today’s AGM logistics announcement fits into this stream of routine corporate disclosures.

Key Terms

general meeting, french commercial code

2 terms

general meeting regulatory

"informs its shareholders that its ordinary and extraordinary general meeting"

A general meeting is a formal gathering of a company’s shareholders where key decisions are discussed and voted on, similar to a town-hall where owners set rules for the business. Investors attend or vote remotely to approve matters such as board members, dividend policies, mergers or major changes, making it a direct way to influence management and protect or change the company’s direction. Outcomes can affect the company’s strategy, governance and share value.

french commercial code regulatory

"The documents referred to in Article R.22-10-23 of the French Commercial Code"

The French Commercial Code is the national rulebook that sets the legal framework for business activity in France, covering company formation and governance, commercial contracts, trade practices, bankruptcy procedures and the role of commercial courts. For investors, it matters because these rules determine how companies are structured, how contracts and disputes are handled, and how creditor and shareholder rights are protected — like an operating manual that shapes business risk and legal recourse.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026
Availability of the Preparatory Documents

PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, informs its shareholders that its ordinary and extraordinary general meeting (the “General Meeting”) will be held on May 11, 2026, at 3:00 pm (CEST), at the hotel Paris Marriott Opera Ambassador, located at 16 boulevard Haussmann in Paris (75009), France.

The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the General Meeting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) of April 3, 2026 (N°2600756).

The information and preparatory documents for this General Meeting are made available to the Company’s shareholders in accordance with the procedures and within the time limits provided for by the applicable legal and regulatory provisions. The documents referred to in Article R.22-10-23 of the French Commercial Code are available on the Company’s website: www.abivax.com

About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

Attachment

• 260420_Abivax_PR_AGM Preparatory Documents

FAQ

When and where is Abivax's (ABVX) Annual Ordinary and Extraordinary General Meeting on May 11, 2026?

The meeting is scheduled for May 11, 2026 at 3:00 pm CEST in Paris. According to Abivax, it will take place at the Paris Marriott Opera Ambassador, 16 boulevard Haussmann, and is open to shareholders following notice procedures.

How can ABVX shareholders access the preparatory documents for the May 11, 2026 General Meeting?

Shareholders can access documents on the company's website. According to Abivax, the documents referred to in Article R.22-10-23 of the French Commercial Code are available at www.abivax.com.

What was published in BALO regarding Abivax (ABVX) before the May 11, 2026 General Meeting?

A preliminary notice of meeting with the agenda and draft resolutions was published in BALO on April 3, 2026 (N°2600756). According to Abivax, this notice informs shareholders how to attend and vote.

How do ABVX shareholders vote at the May 11, 2026 General Meeting if they cannot attend in person?

Shareholders may vote remotely or by proxy following legal procedures. According to Abivax, instructions on how to attend and vote remotely are included in the preparatory documents available on the company website.

What topics will be covered at Abivax's (ABVX) Annual Ordinary and Extraordinary General Meeting on May 11, 2026?

The agenda includes ordinary and extraordinary resolutions for shareholder approval. According to Abivax, the preliminary notice and draft resolutions set out the specific items to be voted on at the meeting.